Nephrology, Adelaide and Meath Hospital, Dublin, Ireland.
Perit Dial Int. 2012 Nov-Dec;32(6):628-35. doi: 10.3747/pdi.2011.00187. Epub 2012 May 1.
Peritoneal dialysis (PD) is the preferred available option of renal replacement therapy for a significant number of end-stage kidney disease patients. A major limiting factor to the successful continuation of PD is the long-term viability of the PD catheter (PDC). Bedside percutaneous placement of the PDC is not commonly practiced despite published data encouraging use of this technique. Its advantages include faster recovery and avoidance of general anesthesia.
We carried out a retrospective analysis of the outcomes of 313 PDC insertions at our center, comparing all percutaneous PDC insertions between July 1998 and April 2010 (group P, n = 151) with all surgical PDC insertions between January 2003 and April 2010 (group S, n = 162).
Compared with group P patients, significantly more group S patients had undergone previous abdominal surgery or PDC insertion (41.8% vs 9.3% and 33.3% vs 3.3% respectively, p = 0.00). More exit-site leaks occurred in group P than in group S (20.5% vs 6.8%, p = 0.002). The overall incidence of peritonitis was higher in group S than in group P (1 episode in 19 catheter-months vs 1 episode in 26 catheter-months, p = 0.017), but the groups showed no significant difference in the peritonitis rate within 1 month of catheter insertion (5% in group P vs 7.4% in group S, p = 0.4) or in poor initial drainage or secondary drainage failure (9.9% vs 11.7%, p = 0.1, and 7.9% vs 12.3%, p = 0.38, for groups P and S respectively).Technical survival at 3 months was significantly better for group P than for group S (86.6% vs 77%, p = 0.037); at 12 months, it was 77.7% and 68.7% respectively (p = 0.126). No life-threatening complications attributable to the insertion of the PDC occurred in either group.
Our analysis demonstrates further encouraging outcomes of percutaneous PDC placement compared with open surgical placement. However, the members of the percutaneous insertion group were primarily a selected subset of patients without prior abdominal surgery or PDC insertion, therefore limiting the comparability of the groups. Studies addressing such confounding factors are required. Local expertise in catheter placement techniques may affect the generalizability of results.
腹膜透析(PD)是大量终末期肾病患者肾替代治疗的首选方法。PD 导管(PDC)长期存活是成功继续 PD 的主要限制因素。尽管有文献鼓励使用这种技术,但床边经皮置管 PD 并不常见。其优点包括更快的恢复和避免全身麻醉。
我们对我们中心的 313 例 PDC 置管的结果进行了回顾性分析,比较了 1998 年 7 月至 2010 年 4 月期间所有经皮 PDC 置管(组 P,n=151)与 2003 年 1 月至 2010 年 4 月期间所有手术 PDC 置管(组 S,n=162)。
与组 P 患者相比,组 S 患者中既往有腹部手术或 PDC 置管史的患者明显更多(分别为 41.8%和 33.3%比 9.3%和 3.3%,p=0.00)。与组 S 相比,组 P 患者的出口部位泄漏更多(20.5%比 6.8%,p=0.002)。组 S 的腹膜炎总发生率高于组 P(19 个导管月发生 1 例,26 个导管月发生 1 例,p=0.017),但导管插入后 1 个月内的腹膜炎发生率无显著差异(组 P 为 5%,组 S 为 7.4%,p=0.4),或初始引流不良或继发性引流失败(分别为 9.9%和 11.7%,p=0.1,7.9%和 12.3%,p=0.38,组 P 和组 S)。组 P 的技术生存率在 3 个月时明显优于组 S(86.6%比 77%,p=0.037),在 12 个月时分别为 77.7%和 68.7%(p=0.126)。两组均未发生与 PDC 插入相关的危及生命的并发症。
我们的分析进一步证明了经皮 PDC 置管与开放式手术置管相比具有更好的结果。然而,经皮置管组的成员主要是一组没有既往腹部手术或 PDC 置管史的选择性患者,因此限制了组间的可比性。需要研究解决这些混杂因素。导管放置技术的本地专业知识可能会影响结果的可推广性。